tyrvaya
·Code: OC-01
tyrvaya: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.
tyrvaya evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
Source-backed records connect tyrvaya to OYST; that link alone does not prove the drug works.
What to watch
Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected
Prepared research question
How could tyrvaya → OYST affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Oyster Point Pharma, Inc. (OYST) | Approved |
Clinical Trials (1)
A Clinical Evaluation of Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg
Primary endpoint: Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Interventionalopen50 targetStarted 2026-07Completion 2027-031 site · United StatesOcular Aesthetics, LLC dba Ocular Clinical Trials
Frequently asked questions
Who is developing tyrvaya?
tyrvaya is being developed by Oyster Point Pharma, Inc..
How many clinical trials involve tyrvaya?
BioSniper tracks 1 clinical trial involving tyrvaya.
What is tyrvaya's latest FDA decision?
The most recent tracked FDA decision for tyrvaya is Approval, dated October 15, 2021.